Simulations Plus (SLP) Stock Price, News & Analysis

Company Overview

Simulations Plus, Inc. develops software and provides consulting services for the pharmaceutical and biotechnology industries. Its tools help researchers model how drugs behave in the body, assess drug properties, and support decisions during drug discovery and development.

The company’s products include GastroPlus for physiologically based pharmacokinetic modeling and simulation, ADMET Predictor for estimating absorption, distribution, metabolism, excretion and toxicity properties, and MonolixSuite for pharmacometrics and quantitative pharmacology. Simulations Plus also offers consulting in areas such as drug development modeling, regulatory strategy and data analysis.

Founded in 1996, Simulations Plus serves pharmaceutical and biotechnology companies, academic researchers and regulatory organizations in the United States and internationally. Its software and services are used across multiple stages of drug development, from early research through clinical development.

Key Stats

• Today's Range: $18.50 to $18.50
• 50-Day Range: $18.41 to $18.50
• 52-Week Range: $11.09 to $21.01
• Volume: N/A
• Average Volume: 253,980 shs
• Market Capitalization: $374.16 million
• P/E Ratio: 46.25
• Dividend Yield: N/A
• Price Target: $17.25
• Consensus Rating: Reduce

Simulations Plus Stock Analysis - MarketRank™

Simulations Plus scored higher than 5% of companies evaluated by MarketBeat, and ranked 865th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Reduce

Consensus Rating

Simulations Plus has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and 1 sell rating.

Downside Risk

Simulations Plus has a consensus price target of $17.25, representing about 6.8% downside from its current price of $18.50.

Amount of Analyst Coverage

Simulations Plus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Simulations Plus is 46.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Simulations Plus is 46.25, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

Price to Book Value per Share Ratio

Simulations Plus has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.60% of the float of Simulations Plus has been sold short.

Short Interest Ratio / Days to Cover

Simulations Plus has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Simulations Plus has recently decreased by 0.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Simulations Plus does not currently pay a dividend.

Dividend Growth

Simulations Plus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Simulations Plus is 60.00%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Simulations Plus this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Simulations Plus insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.10% of the stock of Simulations Plus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.08% of the stock of Simulations Plus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 11/14/2026
• Investor update: 12/02/2026
• Next Earnings (Estimated): 12/07/2026
• Fiscal Year End: 8/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:SLP
• CIK: 1023459
• Web: www.simulations-plus.com
• Phone: (661) 723-7723
• Fax: 661-723-5524
• Employees: 160
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Simulations Plus: $17.25
• High Price Target: $18.50
• Low Price Target: $16.00
• Potential Upside/Downside: -6.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.40
• Trailing P/E Ratio: 46.25
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.72 million
• Net Margins: 9.88%
• Pretax Margin: 15.30%
• Return on Equity: 13.50%
• Return on Assets: 12.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: $82.06 million
• Price / Sales: 4.56
• Cash Flow: $1.43 per share
• Price / Cash Flow: 12.93
• Book Value: $6.20 per share
• Price / Book: 2.98

Miscellaneous

• Outstanding Shares: 20,225,000
• Free Float: 16,362,000
• Market Cap: $374.16 million
• Optionable: Optionable
• Beta: 1.31